Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInvivoscribe, Inc.

About this trial

This protocol describes the pivotal accuracy study for the IdentiClone Dx TRG Assay. The intent of the accuracy study is to demonstrate agreement between the results of the IC TRG Dx Assay and a predicate devise or assay on retrospective and residual de-identified DNA extracted from FFPE (Formalin Fixed Paraffin Embedded) samples from individuals with suspected T-Cell Lymphoproliferations. The predicate device will be the LymphoTrack Dx TRG (FR1/FR2/FR3) Assays - MiSeq (LT Dx TRG-CE-IVD), which is a CE-IVD assay with a similar intended use as the IC TRG Assay on the same sample type.

Eligibility criteria

Qualifiers

De-identified, residual FFPE specimens with a minimum of 8 curls

Subject Age ≥ 18

ICD10 Codes: C84, C85.8, C85.9, C86.1, C86.2, C86.3, C86.5, 86.6, C91.5, C91.6, C91.0, C91.z, C91.9, C94, C95, C96, or other T-cell lymphoma diagnosis

b. T-cell lymphoproliferative disease diagnosis per collection site procedure (e.g., SNOMED)

Disqualifiers

None

Trial design

Treatments tested in this trial

  • IdentiClone Dx TRG Assay

Treatment groups

250 Participants
are divided into 2 treatment groups

Sponsors and collaborators